Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5511796 | 0.91 | MAP2K1 (0.41) | MAP2K1 | |
| SCHEMBL26386555 | 0.85 | KDM1A (0.48) | — | |
| SCHEMBL392027 | 0.83 | MAP2K1 (0.58) | MAP2K1 | |
| SCHEMBL9464838 | 0.82 | PSIP1 (0.59) | MAP2K1 | |
| SCHEMBL10626704 | 0.81 | PTGS2 (0.56) | — | |
| SCHEMBL27183049 | 0.80 | CA2 (0.43) | MAP2K1 | |
| SCHEMBL13855804 | 0.79 | — | — | |
| SCHEMBL25803034 | 0.79 | CA2 (0.62) | MAP2K1 | |
| SCHEMBL4641881 | 0.78 | HPGD (0.41) | MAP2K1 | |
| SCHEMBL905181 | 0.78 | CCR2 (0.54) | TRPV1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106065009-A | As the compound of hepatitis c inhibitor and the application in medicine thereof | 广东东阳光药业有限公司 | 2016-11-02 | — | — | CN | disclosed |
| WO-2015197028-A1 | COMPOUNDS AS HEPATITIS C VIRUS (HCV) INHIBITORS AND USES THEREOF IN MEDICINE | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2015-12-30 | — | — | WO | disclosed |
| WO-2015197028-A1 | COMPOUNDS AS HEPATITIS C VIRUS (HCV) INHIBITORS AND USES THEREOF IN MEDICINE | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2015-12-30 | — | — | WO | disclosed |
| US-8796328-B2 | TRPV1 antagonists | ABBVIE INC. | 2014-08-05 | — | — | US | disclosed |
| US-8642657-B2 | 4-(methyl sulfonyl amino) phenyl analogues as vanilloid antagonist showing excellent analgesic activity and the pharmaceutical compositions comprising the same | GRUENENTHAL GMBH (DE) | 2014-02-04 | — | — | US | disclosed |
| US-20130345255-A1 | TRPV1 ANTAGONISTS | ABBVIE INC. | 2013-12-26 | — | — | US | disclosed |
| US-8273773-B2 | Heterocyclic antiviral compounds | ROCHE PALO ALTO LLC (US) | 2012-09-25 | — | — | US | disclosed |
| EP-2307372-B1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | HOFFMANN LA ROCHE (CH) | 2012-04-25 | — | — | EP | disclosed |
| US-8071650-B2 | Vanilloid receptor modulators; analgesic, antiinflammatory and antiulcer effects; such as 1-(1H-indol-5-ylmethyl)-3-phenethylthiourea | PACIFIC CORPORATION (KR) | 2011-12-06 | — | — | US | disclosed |
| US-8071650-B2 | Vanilloid receptor modulators; analgesic, antiinflammatory and antiulcer effects; such as 1-(1H-indol-5-ylmethyl)-3-phenethylthiourea | PACIFIC CORPORATION (KR) | 2011-12-06 | — | — | US | disclosed |
| EP-1658265-A1 | 4-(METHYL SULFONYL AMINO) PHENYL ANALOGUES AS VANILLOID ANTAGONIST SHOWING EXCELLENT ANALGESIC ACTIVITY AND THE PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | Grünenthal GmbH (DE) | 2006-05-24 | — | — | EP | disclosed |
| WO-2005060692-A2 | BIPHENYL COMPOUNDS AND METHODS | SMITHKLINE BEECHAM CORPORATION (US) | 2005-07-07 | — | — | WO | disclosed |
| WO-2005003084-A1 | 4-(METHYL SULFONYL AMINO) PHENYL ANALOGUES AS VANILLOID ANTAGONIST SHOWING EXCELLENT ANALGESIC ACTIVITY AND THE PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | GRUNENTHAL GMBH (DE) | 2005-01-13 | — | — | WO | disclosed |
| EP-1303483-A4 | NOVEL THIOUREA DERIVATIVES AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME | PACIFIC CORP (KR) | 2004-11-03 | — | — | EP | disclosed |
| US-20030153596-A1 | Novel thiourea derivatives and the pharmaceutical compositions containing the same | PACIFIC CORPORATION (KR) | 2003-08-14 | — | — | US | disclosed |
| EP-1303483-A1 | NOVEL THIOUREA DERIVATIVES AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME | PACIFIC CORPORATION (KR) | 2003-04-23 | — | — | EP | disclosed |
| WO-2002016318-A1 | NOVEL THIOUREA DERIVATIVES AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME | PACIFIC CORPORATION (KR) | 2002-02-28 | — | — | WO | disclosed |
| US-5258399-A | 5-lipoxygenase inhibitors | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1993-11-02 | — | — | US | disclosed |
| US-5236948-A | Lipoxygenase inhibitor | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1993-08-17 | — | — | US | disclosed |
| EP-0495594-A1 | Sulphonamide derivatives | ZENECA LIMITED (GB) | 1992-07-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030153596-A1 | Novel thiourea derivatives and the pharmaceutical compositions containing the same | TAS2R40, TAS1R2, TAS2R45 | MAP2K1 3653/4885TRPV1 18/4885 |
| US-20130345255-A1 | TRPV1 ANTAGONISTS | TRPV1, NPY1R, OPRL1 | MAP2K1 3831/4885TRPV1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.